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Aims: To determine whether initiation of treatment with angiotensin converting
enzyme inhibitors or angiotensin II receptor blockers (ACEI/ARBs) is associated with
a subsequent reduction in haemoglobin in the general population.
Methods: We undertook a national cohort study over a 13-year period (2004–2016),
using routine primary healthcare data from the UK Clinical Practice Research
Datalink. We compared ACEI/ARB initiation with calcium channel blocker (CCB) initi-
ation, to minimise confounding by indication. We included all first ACEI/ARB or CCB
prescriptions in adults with at least 1 haemoglobin result in the 12 months before
and 6 months after drug initiation. Our primary outcome was a ≥1 g/dL haemoglobin
reduction in the 6 months after drug initiation.
Results: We examined 146 610 drug initiation events in 136 655 patients.
Haemoglobin fell by ≥1 g/dL after drug initiation in 19.5% (16 936/86 652) of
ACEI/ARB initiators and 15.9% (9521/59 958) of CCB initiators. The adjusted odds
ratio of a ≥1 g/dL haemoglobin reduction in ACEI/ARB initiators vs CCB initiators
was 1.15 (95% confidence interval 1.12–1.19).
Conclusion: ACEI/ARBs are associated with a modest increase in the risk of a
haemoglobin reduction. For every 100 patients in our study that initiated a CCB,
16 experienced a ≥1 g/dL haemoglobin decline. If the effect is causal, 3 additional
patients would have experienced this outcome if they had received an ACEI/ARB.
This may have implications for drug choice and monitoring for many patients in pri-
mary care. Further research could identify patients at higher risk of this outcome,
who may benefit from closer monitoring.
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1 | INTRODUCTION
Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin
receptor II blockers (ARBs) are widely used for the treatment of heart
failure, hypertension, ischaemic heart disease and proteinuric chronic
kidney disease (CKD).1–4 In health, the renin–angiotensin system
affects renal erythropoietin production and bone marrow
haematopoeisis.5 Randomised data from clinical trials suggests that
ACEI/ARB use is associated with a reduction in haemoglobin.6–8
However, most studies are restricted to specific populations, such as
patients with heart failure, advanced CKD or erythrocytosis after renal
transplantation. Observational data in this area are inconsistent and
limited to restricted patient groups.9–14 There is a lack of evidence on
the effect of ACEI/ARBs on haemoglobin in routine care populations.
Renal insufficiency and elevated baseline haemoglobin may mod-
ify the effect of ACEI/ARBs on haemoglobin, and the effects of ACEIs
and ARBs may differ. However, evidence in these areas is
conflicting.15–18
We examined the association between ACEI/ARBs and
haemoglobin in the UK primary care population. We hypothesised
that initiation of ACEI/ARBs would be associated with a subsequent
haemoglobin reduction. To minimise confounding by indication (which
could give rise to an association between ACEI/ARB initiation and
haemoglobin reduction that is in fact due to the indication for
ACEI/ARB treatment, rather than the drug itself), we compared
patients commencing ACEI/ARBs with patients commencing calcium
channel blockers (CCBs).
2 | METHODS
2.1 | Study design and setting
We performed a cohort study of patients starting treatment with
ACEI/ARBs or CCBs, using the Clinical Practice Research Datalink
(CPRD Gold) as our source population. The CPRD contains real-world
data from over 600 primary care practices, covering a representative
sample of 7% of the UK population.19 The study period was 1 January
2004 to 31 December 2016. We chose this period because CKD is
important in our study and serum creatinine testing became more fre-
quent after the introduction of the Quality and Outcomes Framework
in 2004.20
2.2 | Population, exposure and outcome
We used electronic records of prescriptions and investigation results
to identify patients in CPRD aged ≥18 years that received a new
ACEI/ARB or CCB prescription (Table S1 in the Appendix shows all
generic drug names used) during the study period, and had at least
1 haemoglobin result recorded in primary care in the 12 months
before and 6 months after the date of prescription. To be confident
that prescriptions were truly new and to ensure complete recording
of covariates, we excluded patients with <12 months of continuous
practice registration prior to their first ACEI/ARB or CCB prescription.
Our exposure was ACEI/ARB initiation; our control condition was
CCB initiation. We assumed that patients initiated medications on the
date of the first prescription. We treated ACEI/ARB initiation and
CCB initiation in the same patient as independent events, if separated
by at least 6 months. We considered patients who commenced both
an ACEI/ARB and a CCB within the same 6-month period to be
exposed to the first drug prescribed only.
Our outcome was a ≥1 g/dL haemoglobin reduction in the
6 months following drug initiation. We chose this outcome because
we aimed to study a biological effect of ACEI/ARB initiation that
could be seen at any initial level of haemoglobin, beyond the influence
of natural variation or laboratory measurement error. Previous studies
have demonstrated haemoglobin reductions of this magnitude after
ACEI/ARB initiation.8,21 We calculated haemoglobin change as the
difference between the last result in the 12 months prior to drug initi-
ation (pre-initiation haemoglobin) and the result closest to 115 days in
the 6 months after drug initiation (post-initiation haemoglobin). We
used this method because 115 days is the average lifespan of a red
blood cell.22
2.3 | Covariates
We used clinical knowledge and findings from previous research to
construct a conceptual framework of the relationship between
ACEI/ARB initiation and haemoglobin change (see Figure S1 in the
Appendix). We used this framework to select covariates associated
What is already known about this subject
• Anaemia is associated with worse outcomes in patients
with cardiovascular disease.
• Clinical trial evidence suggests that angiotensin conver-
ting enzyme inhibitors and angiotensin II receptor
blockers (ACEI/ARBs) can cause a reduction in
haemoglobin in restricted patient groups.
• The effect of ACEI/ARB initiation on haemoglobin in rou-
tine care populations is unknown.
What this study adds
• Compared to initiation of a calcium channel blocker, initi-
ation of ACEI/ARB treatment was associated with a 15%
increase in the risk of a ≥1 g/dL haemoglobin reduction.
• If causal, this could impact the quality of life of many
patients who take these widely prescribed medications
and may influence drug choice and monitoring.
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with ACEI/ARB use that are independent risk factors for haemoglobin
reduction.
We used the most recent serum creatinine result in the 12 months
prior to drug initiation to calculate estimated glomerular filtration rate
(eGFR), using the CKD Epidemiology Collaboration equation,23 with-
out ethnicity adjustment. We corrected creatinine results to account
for the standardisation of laboratory measurement.24 We classified
CKD stage as stage 3a, 3b, 4 and 5 (eGFR 45–59, 30–44, 15–29 and
<15 mL/min/1.73m2, respectively).25
We used primary care morbidity coding (Read codes) to identify
comorbidities at drug initiation. These were: hypertension, diabetes
mellitus, ischaemic heart disease, heart failure and conditions that
cause chronic hypoxia (e.g. chronic obstructive pulmonary disease,
cyanotic heart disease). Complete morbidity code lists are available at
https://doi.org/10.17037/data.00001039. We used electronic
records to identify concurrently prescribed medications that can cause
bone marrow suppression or bleeding (see Table S1 in the Appendix).
We recorded calendar period to account for temporal changes in cod-
ing and clinical practice.
2.4 | Statistical analysis
We used t-tests and χ2 tests to compare baseline characteristics
between ACEI/ARB initiators and CCB initiators. For our main anal-
ysis, we used multivariable logistic regression to estimate the
adjusted odds ratio (OR) of a ≥1 g/dL haemoglobin reduction, com-
paring ACEI/ARB initiators and CCB initiators. We initially adjusted
for age group, sex and pre-initiation haemoglobin (<12, 12–13.9,
14–15.9, ≥16 g/dL; minimally adjusted model), before additionally
adjusting for comorbidities (hypertension, diabetes, ischaemic heart
disease, heart failure, CKD, chronic hypoxic conditions), co-
prescribed medications (oral bone marrow suppressing drugs, drugs
that can cause bleeding) and calendar period (2004–2006,
2007–2009, 2010–2012, 2013–2016), and accounting for clustering
at the primary care practice level with robust standard errors (fully
adjusted model).
We handled missing data by performing a complete case analysis.
We performed all analyses using Stata 15.1 (StataCorp, USA) and R
3.3.3 (R Foundation, Austria). All statistical tests were 2-sided and
conducted at a 5% significance level.
2.5 | Sensitivity analyses
In a series of sensitivity analyses, we examined the influence of:
(i) including lifestyle factors (smoking, alcohol intake and body mass
index); (ii) including patients with unknown renal function;
(iii) excluding patients with heart failure and patients taking diuretics;
and (iv) excluding patients initiating both ACEI/ARBs and CCBs on our
results. We also restricted our study cohort by shortening our pre-
initiation period and then by excluding the first 4 weeks from our
post-initiation period. Posthoc, we included only individuals with pre-
initiation haemoglobin measured within 1 week of drug initiation
(Table S2).
2.6 | Propensity score analysis
We performed a propensity score analysis to account for imbalances
in confounders. We calculated propensity scores using a logistic mixed
model including a practice-specific random effect, in which the out-
come was treatment (ACEI/ARB vs CCB) and the covariates were the
same as those in our fully adjusted model. We then used inverse prob-
ability of treatment weighting to create a pseudo-population. To
ensure that we achieved a good balance between treatment groups,
we estimated standardised differences for each covariate before and
after propensity score weighting. We then estimated the average
ACEI/ARB treatment effect using a weighted logistic regression model
that included only the primary exposure and outcome.
2.7 | Additional analyses
We undertook a series of additional analyses to explore further the
relationship between ACEI/ARB initiation and haemoglobin reduction.
2.7.1 | Effect modification
We assessed whether advanced CKD (eGFR <30 mL/min/1.73m2) or
elevated pre-initiation haemoglobin (≥16 g/dL) modified the effect of
ACEI/ARB initiation (compared to CCB initiation) on a ≥1 g/dL
haemoglobin reduction, using Wald tests. Posthoc, we tested for an
interaction between sex and ACEI/ARB initiation in our fully adjusted
model, as there is some evidence that sex modifies erythropoietin
responsiveness.26
2.7.2 | ARB vs ACEI
Because ACEIs and ARBs may affect haemoglobin in different ways,5
we compared the odds of a ≥1 g/dL haemoglobin reduction between
ARB initiators and ACEI initiators, with adjustment for the same
covariates included in our fully adjusted model. We excluded from this
analysis patients who started both an ACEI and an ARB during the
study period.
2.7.3 | Secondary outcomes
To test the consistency of the relationship between ACEI/ARB initia-
tion and haemoglobin reduction, we repeated our fully adjusted model
using incident anaemia (defined as haemoglobin <13 g/dL in men and
<12 g/dL in women)27 following drug initiation as the outcome. We
then used multivariable linear regression to compare absolute
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haemoglobin change between ACEI/ARB and CCB initiators, with
adjustment for the same covariates included in our fully adjusted
model. We also examined the association between ACEI/ARB initia-
tion and diagnosed bone marrow suppression (identified using mor-
bidity codes;see https://doi.org/10.17037/data.00001039) between
1 and 12 months after drug initiation, with adjustment for age, pre-
initiation haemoglobin and use of oral bone marrow suppressing
drugs.
2.7.4 | Haemoglobin variation
We explored whether variation in haemoglobin biased our results,
with two further analyses. Firstly, we predicted that patients with
decreasing haemoglobin prior to drug initiation would be more likely
to experience a haemoglobin reduction after drug initiation. If the
haemoglobin trajectory prior to drug initiation differed between
ACEI/ARB and CCB initiators, our outcome definition could incor-
rectly attribute a haemoglobin reduction to drug initiation. We
assessed this by comparing the average (unadjusted) haemoglobin
change prior to drug initiation (defined as the coefficient of the
regression line of all haemoglobin results in the 12 months prior to
drug initiation) between ACEI/ARB and CCB initiators. We restricted
this analysis to patients with at least 3 haemoglobin results in the pre-
initiation period, so that we had sufficient data to determine a trend.
Any between-group differences in this analysis would suggest that
our outcome definition biased our estimate of the association
between ACEI/ARB initiation and haemoglobin reduction.
Secondly, we hypothesised that a post-initiation haemoglobin
reduction would be more likely in patients with greater natural
haemoglobin variation (i.e. variation over time), due to the phenome-
non known as regression to the mean.28 If ACEI/ARB initiators had
greater natural haemoglobin variation than CCB initiators, the likeli-
hood of a ≥1 g/dL haemoglobin reduction (our primary outcome)
F IGURE 1 Flowchart of cohort creation ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; CCB, calcium
channel blocker; CPRD, clinical practice research datalink
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would be higher in ACEI/ARB initiators at any time in our study
period, irrespective of drug initiation (see Figure S2 in the Appendix
for a graphical illustration of this). We investigated this by comparing
the odds of a ≥1 g/dL haemoglobin reduction after an arbitrarily cho-
sen date (1 January 2010), between patients who initiated ACEI/ARBs
or CCBs at another time in the study period. We restricted this analy-
sis to patients who only initiated an ACEI/ARB or a CCB and had at
least 1 haemoglobin result in the 12 months before and 6 months
after 1 January 2010. We adjusted this analysis for age, sex and initial
haemoglobin (the most recent result before 1 January 2010). Any
between-group difference in this model would be attributable to natu-
ral variation alone, and therefore argue against a causal drug effect in
our main analysis.
3 | RESULTS
The study cohort comprised a total of 146 610 drug initiation events
(86 652 ACEI/ARB and 59 958 CCB) in 136 655 individual patients.
Of these, 9955 patients initiated both an ACEI/ARB and a CCB, and
therefore contributed 2 drug initiation events. Figure 1 shows the
development of the cohort.
The mean age at drug initiation was 64.7 years. Male sex, younger
age, ischaemic heart disease, heart failure and diabetes were more
common in ACEI/ARB initiators than CCB initiators (Table 1). The dis-
tribution of lifestyle variables (smoking, alcohol, body mass index) did
not differ meaningfully between ACEI/ARB initiators and CCB initia-
tors (seeTable S3 in the Appendix).
The mean number of haemoglobin results in the pre-initiation and
post-initiation periods was similar in ACEI/ARB initiators and CCB ini-
tiators. Pre-initiation haemoglobin was 0.19 g/dL (95% confidence
interval [CI] 0.17–0.21) higher in patients initiating ACEI/ARBs com-
pared to CCBs. The prevalence of anaemia at drug initiation was lower
in ACEI/ARB initiators than CCB initiators (15.8 vs 16.7%; OR 0.94,
95% CI 0.91–0.97; Table 2).
A ≥1 g/dL haemoglobin reduction following drug initiation
occurred in 19.5% (16,936/86,652) of ACEI/ARB initiators and 15.9%
(9,521/59,958) of CCB initiators (OR 1.29, 95% CI 1.25–1.32). The
minimally adjusted OR (adjusted for age, sex and pre-initiation
haemoglobin) of a ≥1 g/dL haemoglobin reduction after drug initiation
comparing ACEI/ARB initiators to CCB initiators was 1.24 (95% CI
1.21–1.28). The fully adjusted OR (additionally adjusted for com-
orbidities, co-prescribed medications and calendar period) was 1.15
(95% CI 1.12–1.19; Table 3. Table S4 in the Appendix shows the
mutually adjusted ORs of all covariates in the fully adjusted model).
3.1 | Sensitivity analyses
Our results did not differ meaningfully in any of our sensitivity ana-
lyses, although restriction of the pre-initiation period attenuated the
association between ACEI/ARB initiation and haemoglobin reduction.
In the posthoc analysis restricted to individuals with a pre-initiation
TABLE 1 Characteristics of the study population at drug
initiation. Data are n (column %)
ACEI/ARB initiators
(n = 86 652)
CCB initiators
(n = 59 958)
Male sex 41 222 (47.6) 24 631 (41.1)
Age (y)
18–44 8395 (9.7) 4640 (7.7)
45–49 7466 (8.6) 3363 (5.6)
50–54 9067 (10.5) 4557 (7.6)
55–59 8963 (10.3) 6473 (10.8)
60–64 10 181 (11.7) 8094 (13.5)
65–69 10 430 (12.0) 8563 (14.3)
70–74 10 048 (11.6) 8150 (13.6)
75–79 9360 (10.8) 7327 (12.2)
80–84 7211 (8.3) 5234 (8.7)
85+ 5531 (6.4) 3557 (5.9)
Calendar period
2004–2006 22 925 (26.5) 11 834 (19.7)
2007–2009 25 386 (29.3) 14 792 (24.7)
2010–2012 20 406 (23.5) 16 088 (26.8)
2013–2016 17 935 (20.7) 17 244 (28.8)
Comorbidities
Hypertension 54 917 (63.4) 42 816 (71.4)
Ischaemic heart
disease
20 542 (23.7) 11 591 (19.3)
Heart failure 5428 (6.3) 1082 (1.8)
Diabetes 21 957 (25.3) 11 447 (19.1)
Chronic hypoxic
conditions
16 813 (19.4) 12 900 (21.5)
CKD
None 66 335 (76.6) 45 602 (76.1)
Stage 3a 11 267 (13.0) 6812 (11.4)
Stage 3b 3898 (4.5) 2702 (4.5)
Stage 4 791 (0.9) 913 (1.5)
Stage 5 120 (0.1) 244 (0.4)




1713 (2.0) 1495 (2.5)
Drugs that can cause
bleeding a
29 455 (34.0) 16 274 (27.1)
Pre-initiation haemoglobin (g/dL)
<12 10 680 (12.3) 7960 (13.3)
12–13.9 32 848 (37.9) 25 734 (42.9)
14–15.9 35 093 (40.5) 22 127 (36.9)
≥16 8031 (9.3) 4137 (6.9)
ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor
blocker; CCB, calcium channel blocker; CKD, chronic kidney disease.
aSeeTable S1 for full list of medications.
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haemoglobin within 1 week of drug initiation, a ≥1 g/dL haemoglobin
reduction was associated with CCB initiation (Figure 2; Table S2 in
the Appendix).
3.2 | Propensity score analysis
Our propensity score analysis showed that, after accounting for
potential confounders, the OR of a ≥1 g/dL haemoglobin reduction
after drug initiation comparing ACEI/ARB initiators to CCB initiators
was 1.15 (95% CI 1.11–1.20. Table S5 in the Appendix shows cohort
characteristics before and after propensity score weighting).
3.3 | Additional analyses
3.3.1 | Effect modification
The association between ACEI/ARB initiation and haemoglobin reduc-
tion was weaker among patients with pre-initiation haemoglobin
≥16 g/dL (OR 1.07, 95% CI 0.99–1.16) than among those with pre-
initiation haemoglobin <16 g/dL (OR 1.17, 95% CI 1.13–1.21; P = .03
for interaction). There was no evidence that advanced CKD (eGFR
<30 mL/min/1.73m2) modified the effect of ACEI/ARB initiation on
haemoglobin reduction (P = .31 for interaction; Figure 2). Our posthoc
analyses showed that the association between ACEI/ARB initiation
and haemoglobin reduction was more pronounced in women
(OR 1.23, 95% CI 1.18–1.28) than in men (OR 1.08, 95% CI
1.04–1.13; P < .001 for interaction; Figure 2).
3.3.2 | ARB vs ACEI
Among the 86 652 ACEI/ARB initiators, there were 80 911 ACEI initi-
ators and 5710 ARB initiators; 31 individuals initiated both an ACEI
and an ARB during the study period. There were no major differences
between ACEI initiators and ARB initiators (seeTable S6 in the Appen-
dix). 19.5% (15,787/80,911) of ACEI initiators and 19.9%
(1,135/5,710) of ARB initiators experienced a ≥1 g/dL haemoglobin
reduction after drug initiation. The fully adjusted OR of a ≥1 g/dL
haemoglobin reduction comparing ARB initiators to ACEI initiators
was 1.13 (95% CI 1.05–1.22).
3.3.3 | Secondary outcomes
The incidence of anaemia (defined as haemoglobin <13 g/dL in men
and <12 g/dL in women)27 after drug initiation was 8.8%
(6384/72 943) in ACEI/ARB initiators and 8.0% (3985/49 969) in
CCB initiators. The fully adjusted OR of incident anaemia in
ACEI/ARB initiators compared to CCB initiators was 1.12 (95% CI
1.07–1.17). The fully adjusted absolute haemoglobin reduction was
0.05 g/dL (95% CI 0.04–0.06) greater in ACEI/ARB initiators com-
pared to CCB initiators.
TABLE 2 Haemoglobin results by exposure group
ACEI/ARB initiators
(n = 86 652)
CCB initiators
(n = 59 958)




2.0 (2.1) 2.1 (2.3)
Post-initiation
period
1.5 (1.2) 1.6 (1.3)
Haemoglobin level (g/dL)
(mean [SD])
Pre-initiation 13.9 (1.7) 13.7 (1.7)





13 709 (15.8) 9989 (16.7)
Post-initiation
(incidence)b
6384 (8.8) 3985 (8.0)
ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor
blocker; CCB, calcium channel blocker; SD, standard deviation.
Pre-initiation period: 12 months prior to drug initiation; post-initiation
period: 6 months following drug initiation.
aHaemoglobin <13 g/dL in men or <12 g/dL in women.
bIncidence expressed as n (%) of new cases among patients who were not
anaemic prior to drug initiation.
TABLE 3 Multivariable adjusted odds ratio of a ≥1 g/dL haemoglobin reduction in ACEI/ARB initiators vs CCB initiators
Model Minimally adjusteda Fully adjustedb
Observations 146 610 138 684
Adjusted OR 95% CI Adjusted OR 95% CI
CCB initiators Reference Reference
ACEI/ARB initiators 1.24 [1.21–1.28] 1.15 [1.12–1.19]
OR, odds ratio; CI, confidence interval; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; CCB, calcium channel blocker.
aAdjusted for age, sex and pre-initiation haemoglobin.
bAdditionally adjusted for comorbidities (hypertension, ischaemic heart disease, heart failure, diabetes, chronic hypoxic conditions, chronic kidney disease),
medications (oral bone marrow suppressing drugs, drugs that can cause bleeding), calendar period and clustering at primary care practice level.
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A diagnosis of bone marrow suppression was received by 0.15%
(128/86 652) of ACEI/ARB initiators and 0.19% (112/59 958) of CCB
initiators between 1 and 12 months after drug initiation. After adjust-
ment for age, sex and use of oral bone marrow suppressing drugs,
there was no difference in the odds of diagnosed bone marrow sup-
pression between ACEI/ARB initiators and CCB initiators (OR 0.82,
95% CI 0.63–1.08)
3.3.4 | Haemoglobin variation
There were 16 040 ACEI/ARB initiators and 12 065 CCB initiators
with 3 or more haemoglobin results in the pre-initiation period.
Among these patients, there was no difference in the average
haemoglobin change prior to drug initiation between ACEI/ARB initia-
tors (0.28 g/dL/y) and CCB initiators (0.29 g/dL/y; difference 0.01,
95% CI –0.17 to 0.20).
There were 34 257 individuals with at least 1 haemoglobin result
in the 12 months before and 6 months after 1 January 2010 (our arbi-
trarily chosen date). After adjustment for age, sex and initial
haemoglobin, there was no difference in the odds of a ≥1 g/dL
haemoglobin reduction after 1 January 2010 between patients who,
at another time in the study period, initiated ACEI/ARBs or CCBs
(OR 1.02, 95% CI 0.95–1.09).
4 | DISCUSSION
In this large new-user cohort study, we found strong evidence for an
association between ACEI/ARB initiation and subsequent
haemoglobin reduction. After adjustment for confounders, ACEI/ARB
initiators compared to CCB initiators had 15% higher odds of
a ≥1 g/dL haemoglobin reduction, and 12% higher odds of incident
anaemia. Of 100 CCB initiators in our study, 16 experienced
a ≥1 g/dL haemoglobin decline. If the relationship with drug exposure
was causal, 3 additional patients would have experienced this out-
come if the same 100 patients had initiated an ACEI/ARB instead. In
our study population, approximately 8% of the incidence of our pri-
mary outcome was attributable to ACEI/ARB initiation.
To our knowledge, this is the largest study on this topic, and the
first in a national primary care cohort. Restricting to new users and
examining a longitudinal outcome increases the strength of our find-
ings, and we accounted for the influence of several important
covariates. Our findings were consistent across several secondary
outcomes and sensitivity analyses. Differences in the pre-initiation
trajectory or the natural variation of haemoglobin between ACEI/ARB
and CCB users did not appear to explain our results.
Our study has some limitations. Although our choice of compara-
tor group minimised confounding by indication because hypertension
is the major indication for the prescription of both ACEI/ARBs and
F IGURE 2 Forest plot of main, subgroup and sensitivity analyses: adjusted odds ratio of ≥1 g/dL haemoglobin reduction in ACEI/ARB
initiators vs CCB initiators. ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; CCB, calcium channel blocker; CKD,
chronic kidney disease; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate. a Adjusted for age, sex and pre-
initiation haemoglobin, comorbidities (hypertension, ischaemic heart disease, heart failure, diabetes, chronic hypoxic conditions, chronic kidney
disease), medications (oral bone marrow suppressing drugs, drugs that can cause bleeding), calendar period and clustering at primary care practice
level. b Additionally adjusted for smoking status, alcohol intake and body mass index
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CCBs, the greater degree of comorbidity among ACEI/ARB initiators
makes residual confounding possible. Unmeasured confounders such
as infection, chronic inflammation or nutritional deficiency, which are
not captured reliably by our data source, may have been more preva-
lent in ACEI/ARB initiators. However, ACEI/ARB initiators were youn-
ger and had higher pre-initiation haemoglobin than CCB initiators, and
we found no difference in the haemoglobin change of each group
before drug initiation; these observations are not consistent with
ACEI/ARB initiators being sicker in general, and therefore more likely
to experience a haemoglobin reduction. We were unable to account
for adherence to prescribed medication and did not examine for a
dose–response effect due to limitations of the data. Restricting our
study population to patients with haemoglobin results before and
after drug initiation may have resulted in selection bias towards
patients for whom there was a clinical concern over haemoglobin
change, which may limit generalisability of our findings. Our sensitivity
analyses involving shortening of the pre-initiation period showed a
trend towards lower odds of a ≥1 g/dL haemoglobin reduction among
ACEI/ARB initiators, and lower odds of a reduction in haemoglobin
compared to CCB initiators for people with pre-initiation haemoglobin
measured within 1 week of drug initiation. It is possible that this is
due to misclassification of pre-initiation haemoglobin levels among
people with more historic measures, and that the overall result of the
study is due to residual confounding between users of the drug clas-
ses. However, it is also possible that using only individuals with recent
haemoglobin measures exacerbated selection bias by using only infor-
mation from the sickest participants with lower haemoglobin. Alter-
nately, this selection of more unwell people may have included a
larger number with abnormal circulating volume where
haemoconcentration occurred after ACEI/ARB initiation. Lastly, there
is some evidence that CCBs may increase the risk of gastrointestinal
bleeding29; this could have led us to underestimate the association
between ACEI/ARBs and haemoglobin reduction.
Previous studies have found a stronger association between
ACEI/ARBs and haemoglobin reduction.9 This may be due to restric-
tion to specific patient groups with a higher prevalence of com-
orbidities, such as the elderly10 or patients with heart failure,7 CKD,8
or diabetes.12 However, it is noteworthy that advanced CKD did not
modify the effect of ACEI/ARB initiation on haemoglobin reduction in
our study. The greater effect that we observed in ARB initiators com-
pared with ACEI initiators conflicts with the findings of a previous
study in primary care.15
Our findings of an attenuated association between ACEI/ARB
use and haemoglobin reduction among patients with higher pre-
initiation haemoglobin, and a more substantial effect in women com-
pared to men, warrant further examination.
A causal association between ACEI/ARB initiation and
haemoglobin reduction is plausible. Alterations in intrarenal
haemodynamics could inhibit erythropoietin secretion by increasing
oxygen delivery to renal fibroblasts. A small study demonstrated a
reduction in serum erythropoietin (but not haemoglobin) in healthy
volunteers taking ACEIs,30 which supports this mechanism. Experi-
mental studies have also suggested a direct ACEI/ARB effect on bone
marrow.5,31,32 It is not possible to determine which of these explana-
tions might underpin our findings.
Anaemia in older patients is associated with cognitive decline,
decreased quality of life and increased mortality.33 Because
ACEI/ARBs account for 6% of English primary care prescriptions,34
our findings may have a bearing on drug selection, monitoring and
potentially quality of life for a large number of patients. Our results
are relevant to the assessment of unexplained anaemia and may help
to reduce invasive investigations in some patients. These findings
should not influence treatment of patients where strong clinical trial
evidence of prognostic benefit exists, such as those with heart failure
and reduced left ventricular systolic function.35,36 However, they
merit consideration when treating conditions where other drug clas-
ses are equally effective, particularly in patients with pre-existing
anaemia.
In summary, we found a modest increase in the risk of
haemoglobin reduction after initiation of ACEI/ARB treatment. For
some patients, this degree of haemoglobin reduction could have clini-
cal implications. Further study could identify patients at higher risk of
this adverse outcome, who may benefit from closer monitoring.
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